@FiercePharma: Tuesday's top news: Vertex to slash 370 jobs in shift away from hep C drug Incivek. Report | Follow @FiercePharma
@EricPFierce: Wockhardt profits crater as bans by FDA MHRA start to take a toll. FiercePharmaManufacturing story | Follow @EricPFierce
@CarlyHFierce: Wondering which companies will be hardest-hit by patent losses in 2014? Special report | Follow @CarlyHFierce
> The U.S. Supreme Court may be led to its first case on drug-induced abortions after a ruling Tuesday by Oklahoma's top court that a state law restricting the use of mifepristone is unconstitutional. Story (sub. req.)
> Allergan ($AGN) faces a federal lawsuit from a man who claims his wife died of Botox poisoning after taking the drug for an off-label use. Report
> Funding for R&D on new drugs, vaccines and diagnostics that could fight a growing threat from drug-resistant tuberculosis fell 4.6% to $627.4 million last year. Story (sub. req.)
> China's Shanghai Fosun Pharmaceutical Group reported its 9-month net profit rose 27% to ¥ 1.39 billion ($228 million). Item
> Shares of Questcor Pharmaceuticals ($QCOR) fell 10% in extended trading Tuesday, despite strong earnings, after the company reported that two more regulators had joined the U.S. Attorney in Philadelphia, which is investing the company for marketing of its high-priced Acthar Gel. Story
@FierceMedDev: New feature: Q3's top 5 diagnostics VC deals. Special report | Follow @FierceMedDev
> Kona notches solid results for novel renal denervation tech. Article
> CVRx brings in $12M more for hypertension device trial work. More
> Medtronic eyes faster FDA nod as CoreValve aces pivotal study. News
> Theragenics completes $68M sale to private equity outfit Juniper. Item
Biotech News
@FierceBiotech: Still trending: The ax drops at troubled Merck as big restructuring gets underway. Article | Follow @FierceBiotech
@JohnCFierce: We'll have some hiring news soon. but in the meantime still looking for a savvy devices writer. Also, have my eye out for a U.K. writer. | Follow @JohnCFierce
@DamianFierce: Ex-Calistoga chief Gallagher joins VC Frazier Healthcare to steer biotech bets. ICYMI yesterday | Follow @DamianFierce
@EmilyMFierce: Check out my report on 5 promising preclinical drug programs. Special report | Follow @EmilyMFierce
> Arno Therapeutics banks $30M with billionaire backing and a promising cancer drug. Report
> Immune Design recruits new team, lands $32.5M for cancer immunotherapies. News
> Pfizer bets big on PCSK9 with 'massive' Phase III outcomes study. Story
Biomarkers News
> Hopkins team spotlights biomarkers ratio that tags presymptomatic Alzheimer's. More
> Researchers inch closer to breath test for lung cancer. Report
> Biomarker flags patient response to certain melanoma treatments. Story
> GE wins FDA approval for a second Alzheimer's imaging agent. Item
> Inova picks up rheumatoid arthritis biomarkers from Dutch university. Article
Drug Delivery News
@MichaelGFierce: Nanotech promises new frontier as FDA decides how to regulate. Editor's corner | Follow @MichaelGFierce
> Mesoporous delivery technique allows key compounds to aid stem cell transplant. Article
> Pulmatrix heralds early stage results for COPD dry powder tech. More
> Alnylam pushes for PhI trial of orphan hemophilia RNAi drug. Story
> Dual-surface Janus nanoparticle offers cancer diagnosis, drug delivery. Article
> Layered nanoparticles deliver RNA, chemo for one-two punch. Item
Diagnostics News
@MarkHFierce: DARPA is hard at work at a brain monitoring implant to help combat depression and other conditions. FierceMedicalDevices item | Follow @MarkHFierce
> Quest sued by Myriad in flap over BRCA test patents. Item
> Swedish team tracks down soft tissue pain with PET scanner. Story
> GE Healthcare eyes 2014 for U.S. launch of Alzheimer's imaging agent. More
> NextCODE CEO predicts rapid Dx growth with licensed deCODE sequencing tech. Story
> Johns Hopkins blood test points possible way toward early pancreatic cancer detection. Article
And Finally... Hundreds of thousands of people have had their health insurance canceled, leaving openings for Republicans to again raise questions about the President's pledges concerning the Affordable Care Act. Story